Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03170609 · ClinicalTrials.gov registry record · Phase 2
A Phase 1/2, Randomized, Placebo-controlled, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Adults 18 To 49 Years Of Age
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 365
- Enrollment target
NCT03170609 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 365 participants.
The verdict
NCT03170609, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 365 participants
- Enrollment target
Study Summary
This is the Phase 1/2 first-in-human, randomized, placebo-controlled, observer-blinded study evaluating the investigational multivalent group B streptococcus vaccine. Healthy adults aged 18 to 49 years of age with no history of group B streptococcal vaccination will be randomized to receive either a single intramuscular dose of multivalent group B streptococcus vaccine (various formulations at 3 dose levels) or a placebo (saline control).
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Multivalent group B streptococcus vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 365 participants |
| Start Date | 2017-06-05 |
| Est. Completion | 2018-06-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03170609
The ClinicalTrials.gov registry entry for NCT03170609 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 365 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03170609 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03170609 about?
NCT03170609 is a clinical study titled "A Phase 1/2, Randomized, Placebo-controlled, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Adults 18 To 49 Years Of Age". This is the Phase 1/2 first-in-human, randomized, placebo-controlled, observer-blinded study evaluating the investigational multivalent group B streptococcus vaccine. Healthy adults aged 18 to 49 years of age with no history of group B streptococcal vaccination will be randomized to receive either a...
What is the current status of trial NCT03170609?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 365 participants. The study started on 2017-06-05. Estimated completion is 2018-06-25.
What interventions are being tested in trial NCT03170609?
The interventions under investigation include: Placebo (BIOLOGICAL), Multivalent group B streptococcus vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT03170609?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.